Autonomic tone as a cardiovascular risk factor: The dangers of chronic fight or flight

Mayo Clinic Proceedings

Volumn 77, Issue 1, 2002, Pages 45-54

  Curtis, B M ^a   O'Keefe J H , Jr ^a  

^a Cardiovascular Consultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COCAINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; IPRATROPIUM BROMIDE; METHAMPHETAMINE; METOPROLOL; NIFEDIPINE; PHENYLPROPANOLAMINE; RAMIPRIL; SALBUTAMOL; TERAZOSIN;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; EXERCISE; HEART RATE VARIABILITY; HUMAN; INSULIN RESISTANCE; MORTALITY; PSYCHOSOCIAL ENVIRONMENT; REST; REVIEW; RISK FACTOR; SYMPATHETIC TONE; VAGUS TONE;

EID: 0036144188     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.1.45     Document Type: Review

References (130)

1. Influence of heart rate on mortality among persons with hypertension: The Framingham study
2. Significance of reduction in heart rate in cardiovascular disease
3. GUSTO-I Investigators. Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction
4. Impaired chronotropic response to exercise stress testing as a predictor of mortality
5. Usefulness of impaired chronotropic response to exercise as a predictor of mortality, independent of the severity of coronary artery disease
6. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG
7. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort
8. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: The ARIC Study
9. Fractal analysis of heart rate dynamics as a predictor of mortality in patients with depressed left ventricular function after acute myocardial infarction
10. Heart rate variability and progression of coronary atherosclerosis
11. Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy
12. Reduced heart rate variability and mortality risk in an elderly cohort: The Framingham Heart Study
13. Impact of reduced heart rate variability on risk for cardiac events: The Framingham Heart Study
14. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
15. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction
16. Cardiovascular neural regulation during and after prolonged high altitude exposure
17. Autonomic nervous control of heart rate at altitude (5050 m)
18. A rationale for the use of β-blockers as standard treatment for heart failure
19. Effects of a residential exercise training on baroreflex sensitivity and heart rate variability in patients with coronary artery disease: A randomized, controlled study
20. Circadian variation and triggering of acute coronary events
21. Weekly variation of acute myocardial infarction: Increased Monday risk in the working population
22. Propranolol and the morning increase in sudden cardiac death: The beta-Blocker Heart Attack Trial experience
23. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials
24. Perioperative myocardial ischemia in patients undergoing noncardiac surgery, I: Incidence and severity during the 4 day perioperative period
25. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery
26. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery
27. Sudden changes in heart rate variability during the 1999 Taiwan earthquake
28. Lowdose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)
29. Mechanisms responsible for sympathetic activation by cigarette smoking in humans
30. Insulin resistance and coronary heart disease
31. Improving the adverse cardiovascular prognosis of type 2 diabetes
32. Metabolic syndrome X: A review
33. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans
34. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects
35. Multiple metabolic syndrome is associated with lower heart rate variability: The Atherosclerosis Risk in Communities Study
36. Glucose tolerance and other determinants of cardiovascular autonomic function: The Hoorn Study
37. The value of cardiovascular autonomic function tests: 10 years experience in diabetes
38. Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: Evidence for possible early autonomic dysfunction in insulin-resistant subjects
39. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: Effects of weight loss
40. Association of hyperglycemia with reduced heart rate variability (the Framingham Heart Study)
41. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men
42. Usefulness of β-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease
43. Triggering of myocardial infarction by cocaine
44. Stroke and cocaine or amphetamine use
45. Cardiovascular effects of 3,4-methylenedioxymethamphetamine: A double-blind, placebo-controlled trial
46. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: Data from the Third National Health and Nutrition Examination Survey
47. Phenylpropanolamine and the risk of hemorrhagic stroke
48. The FDA, regulation, and the risk of stroke
49. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids
50. Ephedrine: Safe or lethal? Debate intensifies as supplement becomes the energy booster of choice for athletes
51. FDA asked to ban ephedra products
52. The use of β-agonists and the risk of death and near death from asthma
53. β-Agonists: What is the evidence that their use increases the risk of asthma morbidity and mortality?
54. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma
55. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma
56. Bronchodilators and acute cardiac death
57. Acute respiratory-tract infections and risk of first-time acute myocardial infarction
58. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists
59. Effect of imipramine treatment on heart rate variability measures
60. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma
61. Effect of oral milrinone on mortality in severe chronic heart failure
62. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure
63. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
64. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
65. Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
66. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
67. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure
68. The changing face of sympathetic overactivity in hypertension
69. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines
70. The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina
71. The risk of myocardial infarction associated with antihypertensive drug therapies
72. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
73. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients
74. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
75. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
76. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
77. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
78. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials
79. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure
80. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure
81. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy
82. Prevention of sudden cardiac death with β-blockers
83. Effect of β-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
84. Importance of heart rate in determining β-blocker efficacy in acute and long-term acute myocardial infarction intervention trials
85. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy
86. Major depression, heart rate, and plasma norepinephrine in patients with coronary heart disease
87. Association of depression with reduced heart rate variability in coronary artery disease
88. Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease
89. High plasma norepinephrine levels in patients with major affective disorder
90. Evidence based cardiology: Psychosocial factors in the aetiology and prognosis of coronary heart disease: Systematic review of prospective cohort studies
91. Depression and 1-year prognosis in unstable angina
92. Depression in patients recovering from a myocardial infarction
93. Decreased heart rate variability in men with phobic anxiety (data from the Normative Aging Study)
94. Anxiety and vagal control of heart rate
95. Symptoms of anxiety and risk of coronary heart disease: The Normative Aging Study
96. Association of hostility with coronary artery calcification in young adults: The CARDIA study
97. A meta-analytic review of research on hostility and physical health
98. Triggering of acute myocardial infarction onset by episodes of anger
99. Psychosocial influences on mortality after myocardial infarction
100. Living alone after myocardial infarction: Impact on prognosis
101. Emotional support and survival after myocardial infarction: A prospective, population-based study of the elderly
102. Exaggerated blood pressure responses during mental stress are associated with enhanced carotid atherosclerosis in middle-aged Finnish men: Findings from the Kuopio Ischemic Heart Disease Study
103. Exaggerated reactivity to mental stress is associated with exercise-induced myocardial ischemia in an asymptomatic high-risk population
104. The impact of marital status on survival after an acute myocardial infarction: A population-based study
105. Lack of social participation or religious strength and comfort as risk factors for death after cardiac surgery in the elderly
106. Psychosocial interventions for patients with coronary artery disease: A meta-analysis
107. Stress management and exercise training in cardiac patients with myocardial ischemia: Effects on prognosis and evaluation of mechanisms
108. Walking 10,000 steps/day or more reduces blood pressure and sympathetic nerve activity in mild essential hypertension
109. Exercise conditioning and heart rate variability: Evidence of a threshold effect
110. Triggering of sudden death from cardiac causes by vigorous exertion
111. The paradox of exercise
112. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease
113. Benefits of leisure-time physical activity on the cardiovascular risk profile at older age
114. Physical activity and cardiovascular risk factors among elderly men in Finland, Italy, and the Netherlands
115. Leisure-time physical activity and the risk of primary cardiac arrest
116. Cardiorespiratory fitness and the progression of carotid atherosclerosis in middle-aged men
117. From Inuit to implementation: Omega-3 fatty acids come of age
118. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
119. Fish oil-derived fatty acids docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: The Kuopio Ischaemic Heart Disease Risk Factor Study
120. Diet as preventive medicine in cardiology
121. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART)
122. Fish oil and baroreceptor function in man
123. Effect of fish oil on heart rate variability in survivors of myocardial infarction: A double blind randomised controlled trial
124. Marine n-3 fatty acids, wine intake, and heart rate variability in patients referred for coronary angiography
125. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
126. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction
127. Effects of dietary fish oil on ventricular premature complexes
128. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids
129. Prevention of cardiac sudden death by n-3 fatty acids: A review of the evidence
130. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest